Medical Education

Medical Education Grants

Jazz Pharmaceuticals (Jazz) is committed to improving patient outcomes and providing support in compliance with local regulations.

Therapeutic Areas of Interest

Neuroscience

Narcolepsy (US and Canada Only)

The burden of illness and symptoms associated with Narcolepsy, including cardiometabolic comorbidities and lifelong management of disease
Treatment impact on Narcolepsy and associated comorbidities
The potential impact of excessive sodium intake on health and relevance of this risk in Narcolepsy patients (US and Canada Only)
Screening and diagnostic challenges of Narcolepsy
The impact of delayed diagnosis of Narcolepsy

Idiopathic Hypersomnia (US and Canada Only)

Screening, diagnosis, and management of Idiopathic Hypersomnia
Differentiation of Idiopathic Hypersomnia from other causes of EDS
Symptoms associated with Idiopathic Hypersomnia and the impact of treatment, including efficacy and safety considerations
The burden of illness associated with Idiopathic Hypersomnia, including comorbidities
Validated measures for clinical practice assessment of changes in the severity of Idiopathic Hypersomnia
The potential impact of excessive sodium intake on health and specific relevance of this risk in Idiopathic Hypersomnia patients

Epilepsy

Identification, diagnosis and optimal seizure management of Lennox-Gastaut
Syndrome (LGS), Dravet Syndrome (DS) or Tuberous Sclerosis Complex (TSC)
Management of patient transition from pediatric to adult practices
Management of patients with rare developmental and epileptic encephalopathies
(DEEs) (e.g., LGS, DS, and TSC) beyond seizures
Early epilepsy treatment and improvement of long-term outcomes

Cannabinoid Science

Pre-clinical and clinical research on cannabinoid-based products and medicines including:
- Systemic reviews
- Meta analyses
- Patient case studies
Evaluation of differences in evidence/data presented for cannabinoid-based products submitted for regulatory approval (including, for example FDA, EMA, MHRA, PMDA) including evaluations regarding:
- Clinical trial evidence
- Established and unknown risks and safety profiles associated with different cannabinoid-based products and medicines
Science of cannabinoids (including but not limited to):
- Sources of cannabinoids (eg phytocannabinoids, endocannabinoids, synthetic cannabinoids)
- Endocannabinoid system
- Cannabis plant, phytocannabinoids and active/inactive metabolites
- Pharmacology

Oncology

Acute Myeloid Leukemia (AML)

The role of intensive chemotherapy in the treatment of secondary AML
Identification and timely, actionable diagnosis of high-risk AML subsets (e.g., AML-MRC, tAML)
Different technologies for the delivery of secondary AML treatments
- Treatment of secondary AML to include:
  - Efficacy
  - Safety
  - Impact on quality of life
  - Depth of response, real world data and long-term outcomes
Appropriate management of secondary AML patients in the in-patient and out-patient setting
The AML treatment paradigm (e.g., induction, consolidation, combination therapy, maintenance therapy) and patient management
Clinical and economic burden of secondary AML

Endothelial Related Complications

Recognition, incidence, risk factors, diagnosis and early intervention of VOD/SOS including in the non-transplant setting
VOD/SOS diagnostic criteria, diagnostic techniques, radiologic findings and severity grading in both adult and pediatric patients
Pathophysiology, progressive nature and life-threatening complications of advanced VOD/SOS and other endothelial related complications
Efficacy, safety and mechanism of action of current therapies and patient management for the treatment of VOD/SOS
Clinical and economic burden of VOD/SOS and other post-transplant complications associated with endothelial cell damage
Efficacy and safety of current therapies and patient management for COVID-19 related ARDS and other endotheliitis

Small Cell Lung Cancer (SCLC)

Treatment options in second-line therapy for small cell lung cancer (SCLC)
Current considerations for SCLC therapies including:
- Efficacy
- Safety
- Mechanism of Action
Patient management and safety profiles of SCLC second-line therapies

Acute Lymphoblastic Leukemia (ALL)

The biology of immune response, differentiation and management of asparaginase hypersensitivity reaction vs. infusion reaction and the impact and burden on safety and efficacy
The importance of completing treatment and potential safety or other concerns associated with current clinical mitigation strategies for hypersensitivity reactions
Recognition and management of asparaginase toxicities in the adult/young adult population
Management of pediatric and adult/young adult ALL/LBL with asparaginase (e.g., monitoring, PK, safety, clinical value)
Pediatric inspired protocols in the adult/young adult population
The efficacy and clinical benefits of new asparaginase formulation in ALL/LBL
Asparaginase therapies and combinations beyond ALL/LBL

View our current requests for application.

Eligible educational grant applicants include the following (not an exhaustive list):

Medical Schools
Medical Associations/Medical Societies
Hospitals/Medical Centers
Medical Education Providers

This system is currently accepting requests for medical education meetings, conferences, or symposia; medical center grand rounds lectures; fellowships; enduring medical education activities; and similar educational activities.

In Europe & International (EUR/INT) the system is also accepting requests for medical grants as allowed by local regulations.

The following grant requests are not covered by the educational grant request process: requests for funding educational activities that are promotional in nature (e.g., brand-specific promotional speaker activities); requests for funding activities related to promotion of a commercial product (e.g., commercial exhibits); and operational funding for patient advocacy organizations.

How to Apply

Grant requests should be submitted using the Jazz Pharmaceuticals Request Management System.
All grant requests should be received by Jazz in complete form at least 60 days prior to the commencement of the educational activity for consideration.
The system will guide applicants through the process of determining the request type and the required documents for each request.
Jazz Pharmaceuticals does not control or influence the content of programs or the selection of speakers, authors, or faculty planners.
All decisions regarding support are at the discretion of Jazz and will be communicated by email.
Submission of a request does not guarantee support.
For more information, or for questions regarding the status of a grant request, please email mededgrant@jazzpharma.com.